株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

マンノース-6-リン酸イソメラーゼ(MPI)欠損症 - 疫学予測 2028年

Mannose Phosphate Isomerase (MPI) Deficiency - Epidemiology Forecast to 2028

発行 DelveInsight Business Research LLP 商品コード 911518
出版日 ページ情報 英文 60 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
マンノース-6-リン酸イソメラーゼ(MPI)欠損症 - 疫学予測 2028年 Mannose Phosphate Isomerase (MPI) Deficiency - Epidemiology Forecast to 2028
出版日: 2019年09月01日 ページ情報: 英文 60 Pages
概要

主要6カ国(米国、英国、ドイツ、フランス、イタリア、スペイン)におけるマンノース-6-リン酸イソメラーゼ(MPI)欠損症の2016年の有病数は84人と推計されています。

当レポートでは、主要6カ国(米国、英国、ドイツ、フランス、イタリア、スペイン)のマンノース-6-リン酸イソメラーゼ(MPI)欠損症市場を調査し、市場の概要、疾病の概要、全体および国別の有病数の推移と予測を詳細にまとめています。

目次

第1章 重要洞察

第2章 疾病背景と概要

  • イントロダクション
  • 概要
  • 病態生理
  • 原因
  • 症状
  • 診断

第3章 疫学と患者人口

  • 主な調査結果
  • キーオピニオンリーダーの意見
  • 主要6カ国の仮定と根拠

第4章 主要6カ国のマンノース-6-リン酸イソメラーゼ(MPI)欠損症の有病数

第5章 マンノース-6-リン酸イソメラーゼ(MPI)欠損症の疫学:国別

  • 米国
    • 総診断有病数
    • 有病数:臨床症状別
  • 欧州5カ国
    • ドイツ
      • 総診断有病数
      • 有病数:臨床症状別
    • フランス
      • 総診断有病数
      • 有病数:臨床症状別
    • イタリア
      • 総診断有病数
      • 有病数:臨床症状別
    • スペイン
      • 総診断有病数
      • 有病数:臨床症状別
    • 英国
      • 総診断有病数
      • 有病数:臨床症状別

第6章 付録

  • 出典

第7章 DelveInsightのサービス内容

第8章 免責事項

第9章 DelveInsightについて

図表

List of Tables

Table 1 Prevalent Patient Population of MPI Deficiency in 6MM (2016-2028)

Table 2 Total Diagnosed Prevalent Cases of MPI Deficiency in the US (2016-2028)

Table 3 Prevalence of MPI Deficiency based on Clinical Manifestations in the US (2016-2028)

Table 4 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany (2016-2028)

Table 5 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany (2016-2028)

Table 6 Total Diagnosed Prevalent Cases of MPI Deficiency in France (2016-2028)

Table 7 Prevalence of MPI Deficiency based on Clinical Manifestations in France (2016-2028)

Table 8 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy (2016-2028)

Table 9 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy (2016-2028)

Table 10 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain (2016-2028)

Table 11 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain (2016-2028)

Table 12 Total Diagnosed Prevalent Cases of MPI Deficiency in The UK (2016-2028)

Table 13 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK (2016-2028)

List of Figures

Figure 1 Schematic representation of Mannose Phosphate Isomerase (MPI) key role in glycolysis

Figure 2 Role of Mannose Phosphate Isomerase (MPI) in N-linked glycosylation

Figure 3 Lipid-linked oligosaccharide biosynthetic pathway

Figure 4 Associated Signs and Symptoms of MPI Deficiency

Figure 5 Prevalent Patient Population of MPI Deficiency in 6MM (2016-2028)

Figure 6 Total Diagnosed Prevalent Cases of MPI Deficiency in the US (2016-2028)

Figure 7 Prevalence of MPI Deficiency based on Clinical Manifestations in the US (2016-2028)

Figure 8 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany (2016-2028)

Figure 9 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany (2016-2028)

Figure 10 Total Diagnosed Prevalent Cases of MPI Deficiency in France (2016-2028)

Figure 11 Prevalence of MPI Deficiency based on Clinical Manifestations in France (2016-2028)

Figure 12 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy (2016-2028)

Figure 13 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy (2016-2028)

Figure 14 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain (2016-2028)

Figure 15 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain (2016-2028)

Figure 16 Total Diagnosed Prevalent Cases of MPI Deficiency in The UK (2016-2028)

Figure 17 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK (2016-2028)

目次
Product Code: DIEI0382

DelveInsight's 'Mannose Phosphate Isomerase (MPI) Deficiency - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MPI in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2016-2028

Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology

The Mannose Phosphate Isomerase (MPI) Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US and EU5.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Mannose Phosphate Isomerase (MPI) Deficiency in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2016-2028.

According to DelveInsight, total prevalent population of Mannose Phosphate Isomerase (MPI) Deficiency in six major markets was found to be 84 in 2016.

Mannose Phosphate Isomerase (MPI) Deficiency Report Insights

  • The report covers detailed overview of Mannose Phosphate Isomerase (MPI) Deficiency explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 6 major markets covering the United States and EU5 (Germany, Spain, France, Italy, and UK).
  • The Report highlights the unmet needs of Iron Overload Disorder (IOD).
  • The Report helps to recognize the growth opportunities in the 6MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total diagnosed prevalent patient population and clinical manifestations in 6MM.

Mannose Phosphate Isomerase (MPI) Deficiency Report Key Strengths

  • 10 Year Forecast
  • 6MM Coverage
  • Total diagnosed prevalent cases
  • Prevalence of MPI Deficiency based on Clinical Manifestations

Mannose Phosphate Isomerase (MPI) Deficiency Report Assessment

  • Patient Segmentation based on clinical manifestations
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview

  • 2.1 Introduction
  • 2.2 Facts about Mannose Phosphate Isomerase
  • 2.3 Pathophysiology
  • 2.4 Causes
  • 2.5 Symptoms
  • 2.6 Diagnosis

3. Epidemiology and Patient Population

  • 3.1 Key Findings
  • 3.2 KOL's Views: Epidemiology
  • 3.3 Assumptions and Rationale 6MM

4. 6MM Total Prevalent Patient Population of MPI Deficiency

5. Country Wise-Epidemiology of MPI Deficiency

  • 5.1 The United States
    • 5.1.1 Total Diagnosed Prevalent Cases of MPI Deficiency in the United States
    • 5.1.2 Prevalence of MPI Deficiency based on Clinical Manifestations in the United States
  • 5.2 EU5
    • 5.2.1 Germany
      • 5.2.1.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany
      • 5.2.1.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany
    • 5.2.2 France
      • 5.2.2.1 Total Diagnosed Prevalent Cases of MPI Deficiency in France
      • 5.2.2.2 Prevalence of MPI Deficiency based on Clinical Manifestations in France
    • 5.2.3 Italy
      • 5.2.3.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy
      • 5.2.3.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy
    • 5.2.4 Spain
      • 5.2.4.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain
      • 5.2.4.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain
    • 5.2.5 The United Kingdom
      • 5.2.5.1 Total Diagnosed Prevalent Cases of MPI Deficiency in the UK
      • 5.2.5.2 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK

6. Appendix

  • 6.1 Sources Used

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

Back to Top